44 results about "Organ preservation solution" patented technology

The invention relates to a (KYL) organ preservation solution. The organ preservation solution is prepared from the following raw materials by weight (dosage g / L): 40 to 45 grams of sucrose, 1 to 3 grams of reducibility glutathione, 3 to 4 grams of adenosine triphosphate, 0.12 to 0.18 gram of ulinastatin, 0.6 to 0.8 gram of magnesium sulfate, 0.5 to 0.8 gram of sodium hydroxide, 2 to 3 grams of potassium dihydrogen phosphate, 2 to 4 grams of disodium hydrogen phosphate, 0.6 to 1 gram of radix salviae miltiorrhizae, 0.6 to 0.9 gram of notoginseng, and 10 to 12 grams of glycine. The organ preservation solution has the advantages that: the organ preservation solution has simple preparation and an equivalent preservation effect compared with the UW solution; the organ preservation solution has a better effect than the UW solution regarding the protection for the hepatocyte functions, the hepar microcirculation and the sinus hepaticus endothelial cells; and the organ preservation solution has low price.

The invention provides a quantitative detection method of acetylcysteine related substances in an organ preservation solution. The quantitative detection method is characterized by comprising the steps of: (1) determination of the limits of three acetylcysteine related substances in a preparation; (2) methodology validation of the detection method and determination of the acetylcysteine related substances in the preparation. The quantitative limits of the three related substances are determined by adopting an HPLC (High Performance Liquid Chromatography) detection method with reference to allowed limit values of active ingredient impurities in the preparation and an existing process of the preparation; the methodology validation is carried out on the detection method in the aspects of specificity, linearity, sample injection recovery rate, repeatability, durability and the like to prove that direct injection detection results of a stock solution of the organ preservation solution A are good. The quantitative detection method abandons an inapplicable self-control quantitative method, can be used for realizing the quantitative determination of the acetylcysteine related substances in the organ preservation solution by using an external standard method for the first time and effectively controlling the quality of the organ preservation solution, and is beneficial to the guidance of process study and the improvement of the product safety.

The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

The invention relates to a transplant cold protection bag which is formed by three layers of plastic composite films. A transplanted organ placement bag, a refrigerating bag and a heat insulation bag which are formed by middle films, are mutually closed and are provided with inner films are arranged in a wear-resistant plastic bag of an outer film; the transplant cold protection bag can be used for storing organ preservation solution, transplanted organs, a cool storage material and a heat insulation material which have temperatures of 0 to 4 DEG C; one end of the transplanted organ placement bag, together with the wear-resistant plastic bag, is provided with a transplanted organ taking and storing port formed by two magnets and a sealing material together; and the other end of the transplanted organ placement bag, together with the wear-resistant plastic bag, is provided with a liquid replacement tube with a blockage cap. The transplant cold protection bag disclosed by the invention ensures a low temperature of 0 to 4 DEG C, which is required by transplants in an operation and enables the transplants to have no warm ischemia time; the body temperature of a receptor is prevented from being reduced due to conduction of brine ice gauze and complications are reduced; and the transplants are convenient to move and a touch technology is not adopted. The transplant cold protection bag greatly improves the survival rate of postoperative organs and has important clinical significance and application prospect for storage of the transplants in the organ transplantation and vascular reconstruction process.

Provided is an organ preservation solution for use in transplants which can effectively prevent the occurrence of ischemia reperfusion injury. An organ preservation solution is prepared which contains a blend of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester, L-cysteine, glycine, iron compound and D-glucose.

The current invention provides a new organ preservation solution, suitable for machine perfusion, for maintaining viability of organs, parts of organs and tissues. This solution has been designed to overcome a number of problems associated with hypothermic machine perfusion of donor organs, in particular organs obtained from non-heart-beating donors. The solution prevents or minimizes the adverse affects caused by ischemia, hypoxia, energy and nutrient depletion, acidification, hypothermia and reperfusion injury. The preservation solutions according to the current invention are superior to current state of the art preservation solutions, in particular for preservation and perfusion of organs obtained from non-heart-bearing donors, by supplying increased concentrations and an optimized balance of amino acids, vitamins, anti-oxidants, high molecular weight additives and enhanced buffering capacity. In addition, the preservation solution according to the invention combines optimal physical and chemical properties with the use of readily available, inexpensive and pharmaceutically tested and acceptable compounds, reducing the cost of manufacturing and facilitating medical certification of solutions according to the current invention.

The present invention provides a composition for modulating MARCH-I, MHC II and / or CD86 in the cells of an ex vivo organ, that is to say an organ taken from a donor for subsequent transplantation in a recipient. In one embodiment, the composition comprises one or more organ preservation solutions in combination with an Hsp. In another embodiment, the composition of the invention comprises Hsp70 and / or one or more synthetic Hsp70-derived peptides. The composition of the invention provides preservation while at the same time reducing rejection of an organ, thus offering many advantages and solving various relevant technical problems: not only preserving the useful life of the organ but also initiating a process in the organ which inhibits acute rejection; lengthening the useful life of the organ in vivo; having local immunomodulating effects in the recipient; having an indirect impact on the quality of life of the transplant recipient by necessitating fewer immunossuppressive medications; inducing the activity of regulatory T cells (which are acknowledged to be immunosuppressors), reducing the expression of MHC molecules in the graft, reducing alloreactive expression in the recipient's lymph nodes, and lengthening the survival of the graft in the recipient.

The invention discloses a storage bag special for storing in-vitro broken limbs. The storage bag comprises a first outer bag, a second outer bag and an inner bag positioned inside the first outer bagand the second outer bag, the top of the inner bag is provided with an inlet, a cold storage layer is formed between the inner bag and each of the first outer bag and the second outer bag, and an opening for putting in a coolant is formed in the top outer wall of each of the first outer bag and the second outer bag; a temperature sensor is pasted on the inner wall of the inner bag, a temperature displayer is arranged on the outer wall of the first outer bag, a drainage pipe is arranged at the bottom of the first outer bag, and a first sealing strip and a second sealing strip which are used forsealing the inlet are fixed at the top of the first outer bag and the top of the second outer bag respectively. The storage bag is simple in structure; two layers are adopted to store the broken limbs, organ storage liquid in the inner bag ensures storage effect of the broken limbs, and the cold storage layer between the inner bag and the outer bags realizes cold storage of the broken limbs; temperature of cold storage can be monitored in real time to meet maximum needs of broken limb storage, and survival rate of broken limb re-implantation is increased.

The invention relates to the technical field of medical instruments, and discloses a liver transplantation constant-temperature refrigerator convenient to transfer. The liver transplantation constant-temperature refrigerator convenient to transfer comprises a box body and a box cover; the top of the box body is rotationally connected with the box cover through a hinge; the box cover is buckled with the box body through a buckle; the box body is sequentially provided with an outer shell, an inner shell and a refrigerator body from outside to inside; and the outer shell and the inner shell are of hollow cuboid structures with openings in the upper and lower surfaces. In the process that organ preservation liquid enters a storage box through a liquid discharging pipe, the organ preservation liquid is divided into small liquid drops by a partition net in a temporary storage bag and falls downwards; in the falling process, germs in the preservation liquid can be killed through irradiation of two ultraviolet lamps; and finally, the preservation liquid drops on multiple sealing petals; and after the preservation liquid in the temporary storage bag is accumulated to a certain amount, under the action of gravity, the multiple sealing petals can be flushed open, and the preservation liquid can enter the storage box to be stored, so that the preservation liquid can be continuously used next time.

The invention belongs to medical biology technology, and relates to an organ preservation solution and its preparation. According to the preparation steps per 1000ml, it comprises: taking 1.57mg of tetrahydrobiopterin and 6.92mg of diazoxide and dissolving them in 1ml of dimethyl sulfoxide As a mother liquor; prepare 0.1mol / L CaCl210ml for later use; add 800ml double distilled water into a 1000ml container, add KCl 1.12g, MgCl22.64g, mannitol 10.93g, histidine 4.63g, glutathione 0.92g, Sodium glutamate 3.74g, stir until clear; add sodium lactate 6.90ml, stir until clear; add 0.1mol / L CaCl22.5ml, stir until clear; add stock solution and mother liquor, stir until clear. The pH was adjusted to 7.3-7.5, the osmotic pressure was adjusted to 320Osm / L, and the volume was adjusted to 1000ml with double distilled water. Store at 4°C for low temperature storage.

The invention provides an organ preservation solution and a preparation method thereof, which are characterized in that every 1000ml of organ preservation solution contains: 21 to 29mmol of potassium citrate, 6 to 10mmol of sodium dihydrogen phosphate, 30 to 45mmol of disodium hydrogen phosphate, 4 to 6mmol of magnesium sulfate, 1 to 3mmol of potassium chloride, 16 to 24g of dextran-40, 110 to 150mmol of mannitol, 4 to 6mmol of adenosine, 4 to 6mmol of acetylcysteine, 4 to 6mmol of sodium hydroxide, and the balance water for injection. The organ preservation solution is packaged by a dual-chamber bag, wherein the dextran-40 in the organ preservation solution is arranged in a first chamber and other components are arranged in a second chamber, and a weak welding separation belt is arranged between the adjacent chambers. The organ preservation solution has good stability and lower cost; and the organ preservation solution preparation method has simpler and more reasonable process, and is applicable to large-scale production.

The present invention relates to a cold organ preservation composition for transplantation comprising a cold organ preservation solution and cardiotrophin-1 or a functionally equivalent variant thereof. The invention also relates to methods and kits for the preparation of said composition, the uses thereof for the cold organ protection and / or preservation for transplantation (particularly for kidney, lung and heart) and also to the cold preservation methods and cold-preserved isolated organs by these methods.